Press Releases

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Patent in the U.S.

May 2, 2017

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9 genome editing patent. Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field. Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.

Caribou Biosciences and DuPont Pioneer Develop New Method to Comprehensively Map the Off-Target Activity of CRISPR-Cas9 Across Entire Genomes

May 1, 2017

Breakthrough method will allow researchers to identify CRISPR-Cas9 targets and delivery methods with the highest activity and specificity Caribou and DuPont Pioneer scientists publish paper in Nature Methods describing SITE-Seq

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

April 12, 2017

• Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reversal of the Patent Trial and Appeals Board’s decision to terminate CRISPR/Cas9 interference • In parallel, the companies and their licensors plan to pursue additional patents in the U.S. and worldwide covering the CRISPR/Cas9 technology and its use in cellular and non-cellular settings, including eukaryotic cells

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.

February 15, 2017

UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

December 16, 2016

BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.